{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:50:17Z","timestamp":1792612217161,"version":"4.5.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T00:00:00Z","timestamp":1649894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015735","name":"Helsinki Institute of Life Science, Helsingin Yliopisto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004012","name":"Jane ja Aatos Erkon S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004012","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006383","name":"Sy\u00f6p\u00e4j\u00e4rjest\u00f6t","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006383","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Oncolytic Viruses (OVs) work through two main mechanisms of action: the direct lysis of the virus-infected cancer cells and the release of tumor antigens as a result of the viral burst. In this sc.enario, the OVs act as <jats:italic>in situ<\/jats:italic> cancer vaccines, since the immunogenicity of the virus is combined with tumor antigens, that direct the specificity of the anti-tumor adaptive immune response. However, this mechanism in some cases fails in eliciting a strong specific T cell response. One way to overcome this problem and enhance the priming efficiency is the production of genetically modified oncolytic viruses encoding one or more tumor antigens. To avoid the long and expensive process related to the engineering of the OVs, we have exploited an approach based on coating OVs (adenovirus and vaccinia virus) with tumor antigens. In this work, oncolytic viruses encoding tumor antigens and tumor antigen decorated adenoviral platform (PeptiCRAd) have been used as cancer vaccines and evaluated both for their prophylactic and therapeutic efficacy. We have first tested the oncolytic vaccines by exploiting the OVA model, moving then to TRP2, a more clinically relevant tumor antigen. Finally, both approaches have been investigated in tumor neo-antigens settings. Interestingly, both genetically modified oncolytic adenovirus and PeptiCRAd elicited T cells-specific anti-tumor responses. However, <jats:italic>in vitro<\/jats:italic> cross-representation experiments, showed an advantage of PeptiCRAd as regards the fast presentation of the model epitope SIINFEKL from OVA in an immunogenic rather than tolerogenic fashion. Here two approaches used as cancer oncolytic vaccines have been explored and characterized for their efficacy. Although the generation of specific anti-tumor T cells was elicited in both approaches, PeptiCRAd retains the advantage of being rapidly adaptable by coating the adenovirus with a different set of tumor antigens, which is crucial in personalized cancer vaccines clinical setting.<\/jats:p>","DOI":"10.3389\/fimmu.2022.826164","type":"journal-article","created":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T09:45:27Z","timestamp":1649929527000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Peptides-Coated Oncolytic Vaccines for Cancer Personalized Medicine"],"prefix":"10.3389","volume":"13","author":[{"given":"Sara","family":"Feola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00eblle","family":"Vandermeulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinciane","family":"Fluhler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"De Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manlio","family":"Fusciello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sari","family":"Pesonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erkko","family":"Yl\u00f6sm\u00e4ki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Antignani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Chiaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firas","family":"Hamdan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Feodoroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikaela","family":"Gr\u00f6nholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Cerullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0306-5","article-title":"A Guide to Cancer Immunotherapy: From T Cell Basic Science to Clinical Practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology Meets Immunology: The Cancer-Immunity Cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11033-021-06752-9","article-title":"Harnessing the Immune System Against Cancer: Current Immunotherapy Approaches and Therapeutic Targets","volume":"48","author":"Kumar","year":"2021","journal-title":"Mol Biol Rep"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2373","article-title":"Immunotherapy of Established (Pre)Malignant Disease by Synthetic Long Peptide Vaccines","volume":"8","author":"Melief","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1560919","article-title":"Cancer Vaccines: Designing Artificial Synthetic Long Peptides to Improve Presentation of Class I and Class II T Cell Epitopes by Dendritic Cells","volume":"8","author":"Rabu","year":"2019","journal-title":"Oncoimmunology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.7150\/thno.37194","article-title":"Peptide-Based Materials for Cancer Immunotherapy","volume":"9","author":"Zhang","year":"2019","journal-title":"Theranostics"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.71156","article-title":"A Novel Immunopeptidomic-Based Pipeline for the Generation of Personalized Oncolytic Cancer Vaccines","volume":"11","author":"Feola","year":"2022","journal-title":"eLife"},{"key":"B8","doi-asserted-by":"publisher","first-page":"13404","DOI":"10.1038\/ncomms13404","article-title":"Direct Identification of Clinically Relevant Neoepitopes Presented on Native Human Melanoma Tissue by Mass Spectrometry","volume":"7","author":"Bassani-Sternberg","year":"2016","journal-title":"Nat Commun"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1038\/s41467-020-14968-9","article-title":"Integrated Proteogenomic Deep Sequencing and Analytics Accurately Identify non-Canonical Peptides in Tumor Immunopeptidomes","volume":"11","author":"Chong","year":"2020","journal-title":"Nat Commun"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.696791","article-title":"Beyond Just Peptide Antigens: The Complex World of Peptide-Based Cancer Vaccines","volume":"12","author":"Stephens","year":"2021","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"100022","DOI":"10.1074\/mcp.R120.002309","article-title":"The Peptide Vaccine of the Future","volume":"20","author":"Nelde","year":"2021","journal-title":"Mol Cell Proteom"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3153","article-title":"Novel Cancer Immunotherapy Agents With Survival Benefit: Recent Successes and Next Steps","volume":"11","author":"Sharma","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The Future of Immune Checkpoint Therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The Blockade of Immune Checkpoints in Cancer Immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad0095","article-title":"Genomic Correlates of Response to CTLA-4 Blockade in Metastatic Melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa1348","article-title":"Cancer Immunology. Mutational Landscape Determines Sensitivity to PD-1 Blockade in non-Small Cell Lung Cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"B17","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41392-020-00449-4","article-title":"Advantages of Targeting the Tumor Immune Microenvironment Over Blocking Immune Checkpoint in Cancer Immunotherapy","volume":"6","author":"Tang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B18","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s13046-019-1259-z","article-title":"Combination of CTLA-4 and PD-1 Blockers for Treatment of Cancer","volume":"38","author":"Rotte","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.7150\/thno.58390","article-title":"Turning Cold Tumors Into Hot Tumors by Improving T-Cell Infiltration","volume":"11","author":"Liu","year":"2021","journal-title":"Theranostics"},{"key":"B20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.copbio.2019.11.016","article-title":"Design and Application of Oncolytic Viruses for Cancer Immunotherapy","volume":"65","author":"Ylosmaki","year":"2020","journal-title":"Curr Opin Biotechnol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4663","article-title":"Oncolytic Viruses: A New Class of Immunotherapy Drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat Rev Drug Discovery"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00074","article-title":"Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity","volume":"4","author":"Guo","year":"2014","journal-title":"Front Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/1476-4598-12-103","article-title":"Oncolytic Viruses as Therapeutic Cancer Vaccines","volume":"12","author":"Bartlett","year":"2013","journal-title":"Mol Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2010.121","article-title":"Synergistic Anti-Tumor Effects Between Oncolytic Vaccinia Virus and Paclitaxel are Mediated by the IFN Response and HMGB1","volume":"18","author":"Huang","year":"2011","journal-title":"Gene Ther"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.1038\/s41467-021-22929-z","article-title":"Adjuvant Oncolytic Virotherapy for Personalized Anti-Cancer Vaccination","volume":"12","author":"Roy","year":"2021","journal-title":"Nat Commun"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1105429","article-title":"Oncolytic Adenoviruses Coated With MHC-I Tumor Epitopes Increase the Antitumor Immunity and Efficacy Against Melanoma","volume":"5","author":"Capasso","year":"2016","journal-title":"Oncoimmunology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s40425-019-0644-7","article-title":"Oncolytic Adenovirus Drives Specific Immune Response Generated by a Poly-Epitope pDNA Vaccine Encoding Melanoma Neoantigens Into the Tumor Site","volume":"7","author":"Lopes","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2021.01.014","article-title":"GAMER-Ad: A Novel and Rapid Method for Generating Recombinant Adenoviruses","volume":"20","author":"Hamdan","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B29","article-title":"Targeting Adenovirus to the Serotype 3 Receptor Increases Gene Transfer Efficiency to Ovarian Cancer Cells","volume":"8","author":"Kanerva","year":"2002","journal-title":"Clin Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in Cancer Immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf1490","article-title":"Clonal Neoantigens Elicit T Cell Immunoreactivity and Sensitivity to Immune Checkpoint Blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003292","article-title":"Highly Activated Cytotoxic CD8 T Cells Express Protective IL-10 at the Peak of Coronavirus-Induced Encephalitis","volume":"186","author":"Trandem","year":"2011","journal-title":"J Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.707290","article-title":"Oncolytic Adenovirus: Prospects for Cancer Immunotherapy","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Microbiol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1457596","article-title":"Oncolytic Vaccines Increase the Response to PD-L1 Blockade in Immunogenic and Poorly Immunogenic Tumors","volume":"7","author":"Feola","year":"2018","journal-title":"Oncoimmunology"},{"key":"B35","doi-asserted-by":"publisher","first-page":"3408","DOI":"10.3390\/cancers13143408","article-title":"Therapeutic Cancer Vaccination With Immunopeptidomics-Discovered Antigens Confers Protective Antitumor Efficacy","volume":"13","author":"Peltonen","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-0814","article-title":"Viral Molecular Mimicry Influences the Antitumor Immune Response in Murine and Human Melanoma","volume":"9","author":"Chiaro","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-2062","article-title":"Exploiting Preexisting Immunity to Enhance Oncolytic Cancer Immunotherapy","volume":"80","author":"Tahtinen","year":"2020","journal-title":"Cancer Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2021.02.006","article-title":"Characterization of a Novel OX40 Ligand and CD40 Ligand-Expressing Oncolytic Adenovirus Used in the PeptiCRAd Cancer Vaccine Platform","volume":"20","author":"Ylosmaki","year":"2021","journal-title":"Mol Ther Oncolytics"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-00460-2","article-title":"Advances in the Development of Personalized Neoantigen-Based Therapeutic Cancer Vaccines","volume":"18","author":"Blass","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar7112","article-title":"Personalized Vaccines for Cancer Immunotherapy","volume":"359","author":"Sahin","year":"2018","journal-title":"Science"},{"key":"B41","doi-asserted-by":"publisher","first-page":"967347","DOI":"10.1155\/2012\/967347","article-title":"Cancer Treatment Using Peptides: Current Therapies and Future Prospects","volume":"2012","author":"Thundimadathil","year":"2012","journal-title":"J Amino Acids"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3109\/14653240903164971","article-title":"Binding of Prostate-Specific Membrane Antigen to Dendritic Cells: A Critical Step in Vaccine Preparation","volume":"11","author":"Garetto","year":"2009","journal-title":"Cytotherapy"},{"key":"B43","doi-asserted-by":"publisher","first-page":"973820","DOI":"10.1155\/2012\/973820","article-title":"Prostate-Specific Membrane Antigen-Based Therapeutics","volume":"2012","author":"Akhtar","year":"2012","journal-title":"Adv Urol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/nrc.2017.74","article-title":"Targeting Neoantigens to Augment Antitumour Immunity","volume":"17","author":"Yarchoan","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv382","article-title":"Targeting the Undruggable: Immunotherapy Meets Personalized Oncology in the Genomic Era","volume":"26","author":"Martin","year":"2015","journal-title":"Ann Oncol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.cell.2017.09.050","article-title":"MHC-I Genotype Restricts the Oncogenic Mutational Landscape","volume":"171","author":"Marty","year":"2017","journal-title":"Cell"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau5516","article-title":"Noncoding Regions are the Main Source of Targetable Tumor-Specific Antigens","volume":"10","author":"Laumont","year":"2018","journal-title":"Sci Transl Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2018.6","article-title":"Using Immunotherapy to Boost the Abscopal Effect","volume":"18","author":"Ngwa","year":"2018","journal-title":"Nat Rev Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.826164\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T09:45:31Z","timestamp":1649929531000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.826164\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,14]]},"references-count":48,"alternative-id":["10.3389\/fimmu.2022.826164"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.826164","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,14]]},"article-number":"826164"}}